ArticleFrontiers in nutrition2025
Changes in and relationships between human milk oligosaccharides and microRNAs in milk-derived extracellular vesicles during the first 4 months of lactation.
Article in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Higher expression of SOX1, miR-155, and miR-21 in the colostrum of SARS-CoV-2-infected mothers.Scientific reports · 2026Article
- Bioengineering Interventions to Enhance the Capacity of the Gut Microbiota in Controlling Food Allergies.Life (Basel, Switzerland) · 2026Review
- Longitudinal changes of human milk oligosaccharides in Japan and their associations with maternal or infant characteristics.Frontiers in nutrition · 2026Article
- Synbiotic effects of 2'-fucosyllactose andFrontiers in nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Human milk oligosaccharides (HMOs) exert beneficial effects on the gut microbiota, enhance resistance to infections, support immune development, and contribute to brain/cognitive development. Milk-derived extracellular vesicles (MEVs) contain a high abundance of immunity- and development-related microRNAs (miRNAs). These components are abundant in breast milk. In the case of HMOs, the composition varies due to factors such as lactation stages, geographic location, ethnicity, genetics, and the environment. The composition of HMOs is significantly influenced by the genetic status of two key genes: FUT2 (Secretor gene) and FUT3 (Lewis gene). In this study, we broadly categorized them as secretors or non-secretors. Methods: We investigated the changes in the concentrations of HMOs and MEVs during 4 months of lactation in Japanese women and explored the relationship between HMOs and miRNAs present in MEVs. Results: The concentrations of most HMOs significantly decreased over time. The number of MEVs did not change significantly over the study period. Interestingly, 3'-sialyllactose and lacto-N-fucopentaose III were inversely correlated with many of the top 20 most abundant miRNAs. Moreover, miRNAs in MEVs, which are associated with immunity and development, were more abundant in secretors than in non-secretors during early lactation. Several HMOs were detected in MEVs. Conclusion: This study enabled a detailed characterization of changes in HMOs and MEVs in the breast milk of Japanese women throughout the course of the first 4 months of lactation. A potential association between the concentrations of HMOs and miRNAs was also observed, suggesting that these components might influence each other. These findings are significant for promoting healthy infant development and growth, as well as for improving infant formula composition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.